Executive Interviews

  1. Dermatology — A Growth Opportunity For Those Willing To Risk Colossal Failure
    7/5/2018

    Tom Wiggans, founder, chairman, and CEO of Dermira, provides an overview of the dermatology market, the impetus for founding Dermira, and transparently shares his experience regarding his company’s Phase 3 clinical trial failures.

  2. Sage Therapeutics — Sitting On The Brink Of CNS Breakthroughs
    7/5/2018

    Jeff Jonas, M.D., CEO of Sage Therapeutics, discusses how the company is preparing to launch a new CNS product likely to change the paradigm for how postpartum depression is treated.

  3. Aurinia: Teamwork Twice
    7/5/2018

    From founding the company to funding it, the CEO of Aurinia Pharmaceuticals explains the genesis of the company and why he left retirement to return to guide the company.

  4. Why A Spin-off Is A Win-Win For Big Pharma And Startups
    7/5/2018

    When Viela Bio spun out of MedImmune last spring, it started with some assets well into development. Now it’s focusing on speed and continuity as it advances those assets through the clinic.

  5. What Will The Next 10 Years Bring For Biopharma?
    7/5/2018

    The biopharma industry has changed significantly during the past 10 years, and so has Life Science Leader. What will the next decade have in store for issues such as drug pricing and new therapeutic advances?

  6. Where Are The Most Valuable Lessons Learned?
    6/1/2018

    I imagine George Yancopoulos, profiled on this month’s cover, to have gained some of his life’s wisdom in a similar fashion to most people — by trying new things.

  7. Being A Multicultural Millennial Female In Pharma Manufacturing
    6/1/2018

    Tawni Koutchesfahani, director of manufacturing strategy at Relypsa, says pharmaceutical manufacturing must diversify if it is to thrive. That means the recruitment and retention of more women and more millennials.

  8. Chris Garabedian On How To Drive Drug Development
    6/1/2018

    Drawing from his 27 years in the pharma industry, Chris Garabedian shares useful lessons for combining business savvy and scientific leadership in drug development.

  9. How Wild Ideas Fuel Regeneron’s George Yancopoulos
    6/1/2018

    An exclusive interview with George Yancopoulos who talks about why his partnership with Len Schleifer has lasted so long and how “wild ideas” have served as the underlying theme to Regeneron.

  10. Industry Explorers Blaze On: Vicki Sato — The Biology Biz
    6/1/2018

    Beginning her career with the query — how does biology cause disease? — Vicki Sato progressed to business, turning scientific understanding into new therapeutic drugs. Sato has been a biopharma leader since the industry’s formative years, helping drive the growth of Biogen and Vertex, and she is still guiding new companies today.